User login
Harnessing new data on immunotherapies
Immunotherapies once again took center stage at the 2015 annual meeting of the American Society for Clinical Oncology in Chicago, though many other groundbreaking clinical advances were also presented. The meeting’s theme, “Illumination and innovation: transforming data into learning,” captured the current focus, by both researchers and practicing oncologists, on the importance of being able to draw on new and enticing data and use it as the basis for improving the care of and outcomes for cancer patients.
CheckMate 067: Two immunotherapies better than one for advanced melanoma
Key clinical point Nivolumab alone or combined with ipilimumab significantly improves progression-free survival (PFS) and objective response rates (ORRs), compared with ipilimumab alone in previously untreated metastatic melanoma. Major finding Median PFS was 11.5 months with nivolumab plus ipilimumab, 6.9 months with nivolumab, and 2.9 months with ipilimumab. Data source Phase 3, double-blind randomized trial in 945 patients with previously untreated metastatic melanoma. Disclosures Bristol-Myers Squibb funded the trial. Dr Wolchok reported financial relationships with several firms including research funding from and consulting or advising for Bristol-Myers Squibb…
Click on the PDF icon at the top of this introduction to read the full article.
Immunotherapies once again took center stage at the 2015 annual meeting of the American Society for Clinical Oncology in Chicago, though many other groundbreaking clinical advances were also presented. The meeting’s theme, “Illumination and innovation: transforming data into learning,” captured the current focus, by both researchers and practicing oncologists, on the importance of being able to draw on new and enticing data and use it as the basis for improving the care of and outcomes for cancer patients.
CheckMate 067: Two immunotherapies better than one for advanced melanoma
Key clinical point Nivolumab alone or combined with ipilimumab significantly improves progression-free survival (PFS) and objective response rates (ORRs), compared with ipilimumab alone in previously untreated metastatic melanoma. Major finding Median PFS was 11.5 months with nivolumab plus ipilimumab, 6.9 months with nivolumab, and 2.9 months with ipilimumab. Data source Phase 3, double-blind randomized trial in 945 patients with previously untreated metastatic melanoma. Disclosures Bristol-Myers Squibb funded the trial. Dr Wolchok reported financial relationships with several firms including research funding from and consulting or advising for Bristol-Myers Squibb…
Click on the PDF icon at the top of this introduction to read the full article.
Immunotherapies once again took center stage at the 2015 annual meeting of the American Society for Clinical Oncology in Chicago, though many other groundbreaking clinical advances were also presented. The meeting’s theme, “Illumination and innovation: transforming data into learning,” captured the current focus, by both researchers and practicing oncologists, on the importance of being able to draw on new and enticing data and use it as the basis for improving the care of and outcomes for cancer patients.
CheckMate 067: Two immunotherapies better than one for advanced melanoma
Key clinical point Nivolumab alone or combined with ipilimumab significantly improves progression-free survival (PFS) and objective response rates (ORRs), compared with ipilimumab alone in previously untreated metastatic melanoma. Major finding Median PFS was 11.5 months with nivolumab plus ipilimumab, 6.9 months with nivolumab, and 2.9 months with ipilimumab. Data source Phase 3, double-blind randomized trial in 945 patients with previously untreated metastatic melanoma. Disclosures Bristol-Myers Squibb funded the trial. Dr Wolchok reported financial relationships with several firms including research funding from and consulting or advising for Bristol-Myers Squibb…
Click on the PDF icon at the top of this introduction to read the full article.
Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer
The majority of newly diagnosed lung cancers are NSCLC, and about half of those are adenocarcinomas (Figure 1).2 Over the past decade there has been a significant evolution in the understanding and treatment of lung adenocarcinoma, mostly stemming from a greater appreciation of the distinct pathologies and unique molecular signatures of these tumors. Genomic characterization of the molecular signatures has led to the identification of numerous key genetic alterations that drive lung cancer. The dependency of lung tumors on these genetic drivers has enabled the pharmacological development of targeted therapies that exploit this vulnerability...
Click on the PDF icon at the top of this introduction to read the full article.
The majority of newly diagnosed lung cancers are NSCLC, and about half of those are adenocarcinomas (Figure 1).2 Over the past decade there has been a significant evolution in the understanding and treatment of lung adenocarcinoma, mostly stemming from a greater appreciation of the distinct pathologies and unique molecular signatures of these tumors. Genomic characterization of the molecular signatures has led to the identification of numerous key genetic alterations that drive lung cancer. The dependency of lung tumors on these genetic drivers has enabled the pharmacological development of targeted therapies that exploit this vulnerability...
Click on the PDF icon at the top of this introduction to read the full article.
The majority of newly diagnosed lung cancers are NSCLC, and about half of those are adenocarcinomas (Figure 1).2 Over the past decade there has been a significant evolution in the understanding and treatment of lung adenocarcinoma, mostly stemming from a greater appreciation of the distinct pathologies and unique molecular signatures of these tumors. Genomic characterization of the molecular signatures has led to the identification of numerous key genetic alterations that drive lung cancer. The dependency of lung tumors on these genetic drivers has enabled the pharmacological development of targeted therapies that exploit this vulnerability...
Click on the PDF icon at the top of this introduction to read the full article.
ASCO 2015: from data and learning, to daily practice
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Immunotherapy moves into the breast cancer landscape
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.